Episode 52
Biotech Hangout
00:00
The Adapting U.S. To Bird Feed Exposure
Red X merging with companies in the U.S. which obviously was shareholder driven but this time you know it's essentially a merger of two companies both in the same space slightly different technologies T cell receptor engineering on T cells trying to get off the shelf T cell therapies that are HLA agnostic. If they work would be a phenomenal achievement there is some signs of clinical activity in some of the trials and I see this as a positive positive signal for the sector assuming more such deals will come yeah. It's interesting to see private type financing the structures now come to public markets as the lines between private and public continue to blur.
Transcript
Play full episode
